
Youmna Kfoury

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11896697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. , 2022, 1, 28-44.		32
2	Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell, 2021, 39, 1464-1478.e8.	16.8	98
3	Stress-Induced Changes in Bone Marrow Stromal Cell Populations Revealed through Single-Cell Protein Expression Mapping. Cell Stem Cell, 2019, 25, 570-583.e7.	11.1	96
4	A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia. Cell, 2019, 177, 1915-1932.e16.	28.9	640
5	A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic Syndrome (MDS) in Primary Human Bone Marrow Aspirates. Blood, 2019, 134, 1708-1708.	1.4	1
6	DHODH Inhibitors in the Treatment of Acute Myeloid Leukemia: Defining the Mechanism of Action and the Basis of the Metabolic Therapeutic Window. Blood, 2018, 132, 2716-2716.	1.4	2
7	Osteoblastic Cell-Derived Extracellular Vesicles Transfer Small RNAs That Alter the Physiology of Hematopoietic Cells <i>In Vivo</i> . Blood, 2017, 130, 93-93.	1.4	0
8	Proximity-Based Differential Single-Cell Analysis of the Niche to Identify Stem/Progenitor Cell Regulators. Cell Stem Cell, 2016, 19, 530-543.	11.1	136
9	Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nature Biotechnology, 2016, 34, 738-745.	17.5	176
10	ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood, 2015, 125, 474-482.	1.4	59
11	Mesenchymal Cell Contributions to the Stem Cell Niche. Cell Stem Cell, 2015, 16, 239-253.	11.1	444
12	Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports, 2014, 3, 832-840.	4.8	17
13	SnapShot: The Hematopoietic Stem Cell Niche. Cell, 2014, 158, 228-228.e1.	28.9	19
14	Cellular thrust and parry in the leukemic niche. Blood, 2014, 124, 2760-2761.	1.4	4
15	Proximity-Based Single Cell Analysis of the Bone Marrow Niche Identifies Interleukin-18 As a Quiescence Regulator of Early Hematopoietic Progenitors. Blood, 2014, 124, 773-773.	1.4	1
16	Human T Cell Leukemia Virus Type 2 Tax-Mediated NF-κB Activation Involves a Mechanism Independent of Tax Conjugation to Ubiquitin and SUMO. Journal of Virology, 2013, 87, 1123-1136.	3.4	42
17	Tax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-κB activation. Frontiers in Microbiology, 2013, 4, 231.	3.5	26
18	Animal models on HTLV-1 and related viruses: what did we learn?. Frontiers in Microbiology, 2012, 3, 333.	3.5	37

YOUMNA KFOURY

#	Article	IF	CITATIONS
19	The Multifaceted Oncoprotein Tax. Advances in Cancer Research, 2012, 113, 85-120.	5.0	44
20	Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood, 2011, 117, 190-199.	1.4	60
21	Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects?. Viruses, 2011, 3, 750-769.	3.3	35
22	Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. Journal of Experimental Medicine, 2010, 207, 2785-2792.	8.5	85
23	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-l–associated adult T-cell leukemia/lymphoma. Blood, 2008, 111, 3770-3777.	1.4	36
24	Molecular Mechanisms of NF-kappaB Activation by the HTLV-I Oncoprotein Tax: Role of Post Translational Protein Modification Blood, 2007, 110, 4159-4159.	1.4	0
25	Targeted Therapy with Arsenic Trioxide and Interferon alpha Eradicates Leukemic Cells in SCID Mice Model of Adult T-Cell Leukemia/Lymphoma Blood, 2007, 110, 1379-1379.	1.4	4
26	Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-κB activation. Blood, 2006, 107, 4021-4029.	1.4	98
27	Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene, 2005, 24, 419-430.	5.9	74
28	Tax Ubiquitylation and Sumoylation Control the Two Distinct Steps of NF-κB Activation Blood, 2005, 106, 4353-4353.	1.4	0
29	The Inhibitor of VEGF-Receptors Tyrosine Kinase PTK-787 Blocks the Invasive Potential of Adult T-Cell Leukemia Cells through the Endothelium Blood, 2004, 104, 84-84.	1.4	0